Published in Invest New Drugs on August 10, 2010
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54
Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol (2009) 7.74
Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide. Proc Natl Acad Sci U S A (1984) 2.84
Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res (1975) 2.54
The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) series. Eur J Cancer (1974) 1.15
Experimental solid tumour activity of N-[2-(dimethylamino)ethyl]-acridine-4-carboxamide. Cancer Chemother Pharmacol (1995) 0.95
Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide. Invest New Drugs (2010) 0.87
Current status of amsacrine (AMSA) combination chemotherapy programs in acute leukemia. Cancer Treat Rep (1983) 0.86
Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridin-(5H)ones. Bioorg Med Chem (2005) 0.82
The role of topoisomerases and RNA transcription in the action of the antitumour benzonaphthyridine derivative SN 28049. Cancer Chemother Pharmacol (2008) 0.80
Synthesis and cytotoxic activity of N-[(alkylamino)alkyl]carboxamide derivatives of 7-oxo-7H-benz[de]anthracene, 7-oxo-7H-naphtho[1,2,3-de]quinoline, and 7-oxo-7H-benzo[e]perimidine. Bioorg Med Chem (2005) 0.80
Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice. Cancer Chemother Pharmacol (2009) 0.80
Disrupting tumour blood vessels. Nat Rev Cancer (2005) 4.35
Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells. Cancer Biol Ther (2011) 1.86
In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake. J Inorg Biochem (2007) 1.84
MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivity. Cancer Biol Ther (2010) 1.77
A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem J (2011) 1.57
Thalidomide metabolites in mice and patients with multiple myeloma. Clin Cancer Res (2003) 1.43
5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin Cancer Res (2006) 1.27
Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer (2010) 1.24
Modelling cell death in human tumour cell lines exposed to the anticancer drug paclitaxel. J Math Biol (2004) 1.22
A gene expression signature of invasive potential in metastatic melanoma cells. PLoS One (2009) 1.21
Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors. Front Genet (2013) 1.13
A mathematical model for analysis of the cell cycle in cell lines derived from human tumors. J Math Biol (2003) 1.11
Dual topoisomerase I/II inhibitors in cancer therapy. Curr Top Med Chem (2003) 1.10
Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. Cancer Res (2006) 1.05
Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. Int J Pharm (2008) 1.03
Evolution of the germ line-soma relationship in vertebrate embryos. Reproduction (2011) 1.01
Inhibition of DMXAA-induced tumor necrosis factor production in murine splenocyte cultures by NF-kappaB inhibitors. Oncol Res (2006) 0.98
Epigenetic regulation in human melanoma: past and future. Epigenetics (2015) 0.98
PAX3 knockdown in metastatic melanoma cell lines does not reduce MITF expression. Melanoma Res (2011) 0.97
Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability. Int J Cancer (2005) 0.95
Recurrent cotyledonoid dissecting leiomyoma of the uterus. Int J Gynecol Pathol (2013) 0.94
Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines. BMC Cancer (2012) 0.93
Heterogeneity of expression of epithelial-mesenchymal transition markers in melanocytes and melanoma cell lines. Front Genet (2013) 0.93
Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans. J Pharmacol Exp Ther (2004) 0.92
Variable Expression of GLIPR1 Correlates with Invasive Potential in Melanoma Cells. Front Oncol (2013) 0.91
Centrosomal dysregulation in human metastatic melanoma cell lines. Cancer Genet (2011) 0.91
The role of the hippo pathway in melanocytes and melanoma. Front Oncol (2013) 0.90
Induction of tumour necrosis factor and interferon-gamma in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites. Biochem Pharmacol (2004) 0.90
A comparison of the ability of DMXAA and xanthenone analogues to activate NF-kappaB in murine and human cell lines. Oncol Res (2005) 0.88
Pharmacokinetics and pharmacodynamics of chlorambucil delivered in parenteral emulsion. Int J Pharm (2008) 0.88
The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival. PLoS One (2011) 0.88
Synthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p110alpha inhibitors. Bioorg Med Chem (2007) 0.87
Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide. Invest New Drugs (2010) 0.87
Review of high-dose intravenous vitamin C as an anticancer agent. Asia Pac J Clin Oncol (2014) 0.87
Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours. Cancer Chemother Pharmacol (2006) 0.87
Metabolic control, self-care behaviors, and parenting in adolescents with type 1 diabetes: a correlational study. Diabetes Educ (2010) 0.86
Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients. Clin Cancer Res (2008) 0.86
Modelling the flow [corrected] cytometric data obtained from unperturbed human tumour cell lines: parameter fitting and comparison. Bull Math Biol (2004) 0.86
Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cells. Invest New Drugs (2011) 0.86
Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells. Eur J Pharm Sci (2005) 0.85
Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Invest New Drugs (2007) 0.84
MITF and PAX3 Play Distinct Roles in Melanoma Cell Migration; Outline of a "Genetic Switch" Theory Involving MITF and PAX3 in Proliferative and Invasive Phenotypes of Melanoma. Front Oncol (2013) 0.84
Activin is a potent growth suppressor of epithelial ovarian cancer cells. Cancer Lett (2009) 0.83
Uptake of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and activation of NF-kappaB in human tumor cell lines. Oncol Res (2002) 0.83
NF-kappaB-independent induction of endothelial cell apoptosis by the vascular disrupting agent DMXAA. Anticancer Res (2007) 0.82
Using a stem cell and progeny model to illustrate the relationship between cell cycle times of in vivo human tumour cell tissue populations, in vitro primary cultures and the cell lines derived from them. J Theor Biol (2009) 0.82
Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients. Clin Cancer Res (2004) 0.82
Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridin-(5H)ones. Bioorg Med Chem (2005) 0.82
The role of topoisomerases and RNA transcription in the action of the antitumour benzonaphthyridine derivative SN 28049. Cancer Chemother Pharmacol (2008) 0.80
Synthesis and cytotoxic activity of N-[(alkylamino)alkyl]carboxamide derivatives of 7-oxo-7H-benz[de]anthracene, 7-oxo-7H-naphtho[1,2,3-de]quinoline, and 7-oxo-7H-benzo[e]perimidine. Bioorg Med Chem (2005) 0.80
Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice. Cancer Chemother Pharmacol (2009) 0.80
Novel pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR. Bioorg Med Chem (2011) 0.80
Pharmacokinetics and pharmacodynamics of chlorambucil delivered in long-circulating nanoemulsion. J Drug Target (2010) 0.80
Parental perceptions of sibling relationships in families rearing a child with a chronic condition. J Pediatr Nurs (2010) 0.80
Spirituality as a coping resource for African American parents of chronically ill children. MCN Am J Matern Child Nurs (2010) 0.80
Modelling cell population growth with applications to cancer therapy in human tumour cell lines. Prog Biophys Mol Biol (2004) 0.80
Estimation of radiation-induced interphase cell death in cultures of human tumor material and in cell lines. Oncol Res (2004) 0.79
Cultures of surgical material from lung cancers. A kinetic approach. Methods Mol Med (2003) 0.79
Central serous chorioretinopathy secondary to childbirth. BMJ Case Rep (2010) 0.79
Strategies to maximize liposomal drug loading for a poorly water-soluble anticancer drug. Pharm Res (2014) 0.79
Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice. Cancer Chemother Pharmacol (2002) 0.79
Measuring exercise self-efficacy in pregnant women: psychometric properties of the pregnancy-exercise self-efficacy scale (P-ESES). J Nurs Meas (2013) 0.78
Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs. Invest New Drugs (2008) 0.78
Synthesis and evaluation of unsymmetrical bis(arylcarboxamides) designed as topoisomerase-targeted anticancer drugs. Bioorg Med Chem (2002) 0.78
Synthesis and cytotoxic activity of N-(2-diethylamino)ethylcarboxamide and other derivatives of 10H-quindoline. Bioorg Med Chem (2002) 0.78
Type 1 diabetes: children and adolescents' knowledge and questions. J Adv Nurs (2009) 0.78
Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling. Clin Cancer Res (2003) 0.78
5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. Invest New Drugs (2002) 0.78
Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide. Cancer Chemother Pharmacol (2007) 0.78
The ubiquitin-proteasome system is inhibited by p53 protein expression in human ovarian cancer cells. Cancer Lett (2010) 0.78
Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by liquid chromatography with fluorescence detection: application to transport studies. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 0.77
Increased paired box transcription factor 8 has a survival function in glioma. BMC Cancer (2014) 0.77
Mathematical determination of cell population doubling times for multiple cell lines. Bull Math Biol (2012) 0.77
Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Oncol Res (2003) 0.77